The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Proposal for a Serology-Based Approach to Membranous Nephropathy
Open accessAbstract
Primary membranous nephropathy (MN) is an autoimmune disease mainly caused by autoantibodies against the recently discovered podocyte antigens: the M-type phospholipase A2 receptor 1 (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A). Assays for quantitative assessment of anti-PLA2R antibodies are commercially available, but a semiquantitative test to detect anti-THSD7A antibodies has been only recently developed. The presence or absence of anti-PLA2R and anti-THSD7A antibodies adds important information to clinical and immunopathologic data in discriminating between primary and secondary MN. Levels of anti-PLA2R antibodies and possibly, anti-THSD7A antibodies tightly correlate with disease activity. Low baseline and decreasing anti-PLA2R antibody levels strongly predict spontaneous remission, thus favoring conservative therapy. Conversely, high baseline or increasing anti-PLA2R antibody levels associate with nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation of immunosuppressive therapy. Serum anti-PLA2R antibody profiles reliably predict response to therapy, and levels at completion of therapy may forecast long-term outcome. Re-emergence of or increase in antibody titers precedes a clinical relapse. Persistence or reappearance of anti-PLA2R antibodies after kidney transplant predicts development of recurrent disease. We propose that an individualized serology-based approach to MN, used to complement and refine the traditional proteinuria-driven approach, will improve the outcome in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationM-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Tomas, N. M., Beck, L. H., Meyer-Schwesinger, C., Seitz-Polski, B., Ma, H., Zahner, G., Dolla, G., Hoxha, E., Helmchen, U., Dabert-Gay, A.-S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409354 · Cited by 945
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 865
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Fessler, B. J., Ding, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213277 · Cited by 728
Self-citationRituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
Beck, L. H., Fervenza, F. C., Beck, D. M., Bonegio, R. G. B., Malik, F. A., Erickson, S. B., Cosio, F. G., Cattran, D. C., & Salant, D. J. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111125 · Cited by 471
Self-citationRuggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070640 · Cited by 376
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care
Ronco, P., & Debiec, H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60731-0 · Cited by 369
Hoxha, E., Thiele, I., Zahner, G., Panzer, U., Harendza, S., & Stahl, R. A. K. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040430 · Cited by 353
Cited by
Primary Membranous Nephropathy
Couser, W. G. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11761116 · Cited by 690
Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy
Sethi, S., Debiec, H., Madden, B., Charlesworth, M. C., Morelle, J., Gross, L., Ravindran, A., Buob, D., Jadoul, M., Fervenza, F. C., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.014 · Cited by 360
Self-citationFloege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
Self-citation
Metadata
- Authors
- De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S., & Fervenza, F. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-10-24
- Volume
- 28
- Issue
- 2
- Pages
- 421-430
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2532400747
- Cited by
- 372
- References
- 24
- FWCI
- 24.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Proposal for a Serology-Based Approach to Membranous Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2016070776
- The paper
- De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S., & Fervenza, F. C. (2017). A Proposal for a Serology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2016070776
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.